Six-year follow-up of adjuvant pertuzumab plus trarstuzumab for early HER2-positive breast cancer

Prof. Martine Piccart

Six-years follow-up of the multinational phase 3 APHINITY trial confirmed the IDFS benefit from adding pertuzumab to standard adjuvant chemotherapy plus trastuzumab for patients with node-positive HER2-positive early breast cancer. Longer follow-up is needed to fully assess overall survival benefit.